Quote | Nuvectis Pharma Inc. (NASDAQ:NVCT)
Last: | $6.43 |
---|---|
Change Percent: | 2.64% |
Open: | $7 |
Close: | $6.43 |
High: | $7 |
Low: | $6.41 |
Volume: | 182,955 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
News | Nuvectis Pharma Inc. (NASDAQ:NVCT)
2024-05-07 10:35:46 ET More on Nuvectis Pharma Seeking Alpha’s Quant Rating on Nuvectis Pharma Historical earnings data for Nuvectis Pharma Financial information for Nuvectis Pharma Read the full article on Seeking Alpha For further details see...
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDA Data presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell lines Sev...
Message Board Posts | Nuvectis Pharma Inc. (NASDAQ:NVCT)
Subject | By | Source | When |
---|---|---|---|
NVCT HIGHLIGHTS: | conix | investorshub | 05/23/2022 8:34:30 PM |
wow from $3 to almost $21 | TheFinalCD | investorshub | 05/18/2022 4:47:20 PM |
$27 we come | ipo_dude | investorshub | 05/18/2022 4:50:08 AM |
znewcar1: NVCT 21% v1,1M c10.25 f12,7M H11.04 ML6.02 | znewcar1 | investorshangout | 04/06/2022 8:48:48 PM |
WOW $7 MOVE 3-10 | TheFinalCD | investorshub | 02/07/2022 9:06:55 PM |
News, Short Squeeze, Breakout and More Instantly...
Nuvectis Pharma Inc. Company Name:
NVCT Stock Symbol:
NASDAQ Market:
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDA Data presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell lines Sev...
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in Tagrisso TM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib, the Active Ingredient in Alecensa TM Fort Lee, NJ, April 08,...
2024-03-24 15:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...